(Q51119875)

30 March 2018

title

Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma. (English)

1 reference

30 March 2018

1 reference

Yasuyuki Arai

1

0 references

author name string

Kouhei Yamashita

2

1 reference

30 March 2018

Kiyomi Mizugishi

3

1 reference

30 March 2018

Momoko Nishikori

4

1 reference

30 March 2018

Masakatsu Hishizawa

5

1 reference

30 March 2018

Tadakazu Kondo

6

1 reference

30 March 2018

Toshiyuki Kitano

7

1 reference

30 March 2018

Hiroshi Kawabata

8

1 reference

30 March 2018

Norimitsu Kadowaki

9

1 reference

30 March 2018

Akifumi Takaori-Kondo

10

1 reference

30 March 2018

publication date

17 August 2014

1 reference

30 March 2018

published in

Hematology

1 reference

30 March 2018

volume

20

1 reference

30 March 2018

issue

4

1 reference

30 March 2018

page(s)

196-202

1 reference

30 March 2018

The mechanisms of action of rituximab in the elimination of tumor cells

cites work

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

B-cell depletion in the treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

The late adverse events of rituximab therapy--rare but there!

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Neutropenia after rituximab treatment: new insights on a late complication

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Cellular niches controlling B lymphocyte behavior within bone marrow during development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Aging in the lympho-hematopoietic stem cell compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

The colony-stimulating factors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845414Y.0000000188

10.1179/1607845414Y.0000000188

21 January 2018

Identifiers

DOI

1 reference

30 March 2018

1 reference

30 March 2018